News

SAGA Wins a SKAPA Innovation Award!

SAGA Diagnostics’ CEO Lao Saal (pictured 3rd from left) and CTO Anthony George were awarded the prestigious SKAPA Foundation Innovation Award in the Memory of Alfred Nobel for their development of ultrasensitive technologies to measure circulating tumor DNA.  Lao and Anthony are among two regional winners for Skåne in south…

SAGA wins 1st Place in NLSDays 2017 StartUp Pitch Competition!

Out of 16 Nordic companies, SAGA Diagnostics won 1st place for best pitch in the Nordic Life Science Days 2017 StartUp Pitch Competition, a Bionordic event sponsored by Johnson & Johnson Innovation, SmiLe Incubator and Medeon Science Park & Incubator. The award includes mentoring from Johnson & Johnson Innovation and complimentary registration…

CEO Lao Saal interviewed by BBC World News

SAGA Diagnostics CEO, Lao Saal, recognized expert on cancer genomics and precision medicine, was invited for a live TV interview by the BBC World News on July 4th 2017.  View the 3-minute clip here https://www.linkedin.com/feed/update/urn:li:activity:6288117550924599297/.

Biotech Leader Bio-Rad to Evaluate SAGA Diagnostics’ Technology

LUND, Sweden — /June 14, 2017/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive monitoring of circulating tumor DNA in cancer patients, today announces an agreement with a global provider of life science and clinical diagnostic products, Bio‑Rad Laboratories, Inc. (NYSE: BIO and BIOb),…

GenomeWeb Webinar, March 9

Tune in on March 9, 2017, or watch the recording, and hear our founder and CEO Lao Saal present an overview of SAGA’s technologies and research results during a webinar hosted by GenomeWeb.  Follow the link https://www.genomeweb.com/resources/webinars/advances-liquid-biopsy-complementary-use-ngs-and-digital-pcr.

CEO presents at Precision Medicine World Conference in Silicon Valley, January 25

CEO Lao Saal invited to present at a premier meeting of global leaders, the Precision Medicine World Conference 2017, held in Silicon Valley, California, January 23-25.  Results from KROMA and IBSAFE are highlighted. See also related press release.

With two new appointments, SAGA Diagnostics strengthens its Board of Directors and Scientific Advisory Board

SAGA Diagnostics AB, a premier provider of cancer genomics testing and non-invasive molecular diagnostics for precision oncology, today announces the appointment of veteran life science executive Gregory Batcheller as a member of the Company’s board of directors, and also the appointment of the world-renowned cancer biochemist Anne-Lise Børresen-Dale to the…

Dr. Saal awarded prestigious grants

Dr. Lao Saal, Founder and CEO for SAGA Diagnostics, was recently awarded two major grants: Swedish Research Council (Vetenskapsrådet): 4 year project grant including specific aim on circulating tumor DNA as a clinical biomarker; 4 million SEK. Swedish Cancer Society (Cancerfonden): 3 year project grant including specific aims on circulating tumor DNA…

Loman and Saal ctDNA paper

Commentary on circulating tumor DNA liquid biopsies in breast cancer, authored by Dr. Niklas Loman and SAGA Diagnostics CEO Dr. Lao Saal, was published in the Annals of Translational Medicine (open access; http://atm.amegroups.com/article/view/12076/pdf).

Come meet us at these upcoming events!

Come meet the SAGA Diagnostics team!  We will be attending the following conferences: Sept 13-15 : Nordic Life Science Days 2016 in Stockholm, Sweden (http://www.nlsdays.com).  CEO Lao Saal will be presenting on Thursday Sept 15 during the Super Session 6, 8:30 to 9:30 • Oncology Diagnostics 2020 – new tools for precision oncology • Plenary Room…